Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

John Quackenbush (co-chair) is currently Professor of Computational Biology and Bioinformatics at the Dana Farber Cancer Institute and the Harvard School of Public Health. Until early 2005, he was an Investigator at The Institute for Genomic Research in Rockville, MD. His primary research areas are functional genomics and bioinformatics and his work has focused on the integration of diverse data types to provide insight into biological systems. He and his group have been investigating gene expression patterns in animal models with the goal of identifying mechanisms underlying a range of human diseases. They have also used microarrays to look for diagnostic and prognostic expression fingerprints in human breast and colon cancer and he has been active in using plant models to develop methods for integrating functional genomics and metabolomics approaches. Dr. Quackenbush earned a Ph.D. in theoretical particle physics form the University of California, Los Angeles.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »